Czechoslovak researchers reported in the 1950s that cannabis extracts killed bacteria. Italian and British chemists confirmed it in 2008: they found potent activity against methicillin-resistant Staphylococcus aureus (MRSA). Since then the idea has been tested in mice and in early human trials. Eighteen years on, there is still no licensed cannabinoid antibiotic. The reasons why are the most useful part of this article.
This describes laboratory research and early-stage trials. Nothing here is a treatment for any infection, and no cannabinoid is licensed as an antibacterial anywhere. Bacterial infections require proper diagnosis and appropriate antibiotics. In Thailand cannabis flower is a controlled herb dispensed only on prescription form PT 33.
1. The Old Research
The antibacterial line starts in Olomouc, Czechoslovakia. There Jan Kabelík, Zdeněk Krejčí and František Šantavý screened more than 3,000 plant species for antibacterial substances, and the screen led them to cannabis. Their first results were published in Lékařské listy in 1952. More appeared in a 1955 Olomouc university conference volume and in Die Pharmazie (1957–1959). They summarised the work in English in Kabelík J, Krejčí Z, Šantavý F. “Cannabis as a medicament.” Bulletin on Narcotics 1960; 12(3): 5–23 (UN Office on Drugs and Crime). That paper covers how they isolated the antibacterial substances, their bacteriological experiments and their clinical experience.
Cannabinoids were also studied against viruses. Blevins and Dumic (Journal of General Virology, 1980; 49: 427–431) reported that THC blocked herpes simplex virus types 1 and 2 from replicating in cell culture. Later studies of THC and herpes viruses did not all agree.
The modern evidence for activity against Neisseria gonorrhoeae, the bacterium that causes gonorrhoea, comes from Blaskovich and colleagues in 2021 (section 3).
2. The Confirmation
Appendino G, Gibbons S, et al., “Antibacterial cannabinoids from Cannabis sativa: a structure–activity study,” Journal of Natural Products, 2008; 71(8): 1427–1430. This was a collaboration between Italian and British researchers.
The finding: all five major cannabinoids tested showed potent activity against several MRSA strains. This held even though these strains resist conventional antibiotics. The authors concluded that the high potency points to a specific mechanism, but they did not identify it.
That is why the paper attracted attention. MRSA is defined by its resistance to a whole class of drugs. A compound that kills it by a route the resistance machinery does not cover is not just another antibiotic. It is potentially a different kind of answer. Later work (section 3) suggests the main target is the bacterial cell membrane.
The suggestion of a cream comes from press coverage, not from the paper. In September 2008 news reports quoted the researchers as saying cannabis-based creams could be developed for persistent skin infections. Appendino told MIT Technology Review that the most practical use would be as topical agents for ulcers and wounds.
3. Eighteen Years Later: From the Dish to Early Trials
There is still no licensed cannabinoid antibacterial. But the hypothesis has not been ignored. Since 2008 it has been tested in animals and in early human trials:
- Farha et al., ACS Infectious Diseases, 2020 (McMaster University). The team screened 18 cannabinoids against MRSA. Cannabigerol (CBG) worked best, including against biofilms and “persister” cells that tolerate antibiotics. CBG appears to act on the bacterial membrane, and it was effective in mice infected with MRSA. The authors flagged a limit: CBG is also toxic to host cells. The lead investigator called this “a therapeutic window, but a narrow one.”
- Blaskovich et al., Communications Biology, 2021 (University of Queensland). Synthetic CBD was active against more than 20 types of Gram-positive bacteria, including MRSA, Streptococcus pneumoniae and Clostridioides difficile. It also killed a small group of Gram-negative bacteria: Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis and Legionella pneumophila. It did not kill most Gram-negatives, such as E. coli or Pseudomonas. In mouse skin infections, a 5% topical CBD preparation cut bacterial numbers compared with an inactive base, but it was less effective than standard 2% mupirocin. Given by mouth or by injection, it did not work against a deep MRSA infection. The authors called this lack of systemic activity CBD’s “Achilles heel.”
- Botanix BTX 1801 (synthetic CBD, nasal). In February 2021 Botanix reported a randomised, double-blind, vehicle-controlled Phase 2a study in healthy volunteers who carried S. aureus in their nose. The company said its ointment and gel were safe and well tolerated, and cleared the bacteria in up to about three-quarters of participants by day 7. The effect faded by day 28. These are company-reported results. The US FDA gave the programme Qualified Infectious Disease Product status. A Phase 2b study in haemodialysis patients was planned. We could not find published results from it.
- Botanix BTX 1503 (topical synthetic CBD, acne). A Phase 2 trial in 368 patients with moderate-to-severe acne (NCT03573518) reported in October 2019. It did not meet its primary endpoint, the reduction in inflammatory lesions at 12 weeks. Acne involves bacteria, inflammation and oil production together, so this was not a pure antibacterial test.
So the honest position has changed. The topical hypothesis has been tested in early trials, with mixed results, and there is still no licensed product. The gap has specific reasons, not suppression:
Topical only, realistically. Concentrations that kill bacteria in a dish are hard to reach in the body. CBD also binds heavily to blood proteins, which Blaskovich’s group named as the likely reason it failed systemically. This is the same gap between dish and bloodstream that comes up in the Cancer topic (1308). For a systemic antibiotic that is a serious obstacle. Applied to the skin or inside the nose, where the concentration is controlled at the surface, it is manageable. That is exactly where the trials have gone.
Formulation is genuinely difficult. Cannabinoids are highly fat-soluble and poorly water-soluble. Making a preparation that holds a stable, effective concentration, reaches the right depth of skin and stays active on the shelf is a real pharmaceutical problem.
Toxicity and margin. The CBG work showed that killing bacterial membranes can also harm human cells. The useful dose range may be narrow.
Resistance. Early studies found that bacteria did not readily become resistant. But bacteria evolve against everything. A new mechanism buys time, not permanence.
Antibiotic development economics are broken. This is the largest obstacle and the least discussed. New antibiotics are used sparingly, for short courses, and are often held in reserve. That earns far less than a drug taken daily for life, which is why many major pharmaceutical companies have left antibiotic development. The cannabinoid programmes above were run by academic groups and a small company. That is typical of how new antibacterials progress now: slowly, and often not to approval.
4. What Would Make This Real
Most of the pieces are already in place: a topical or nasal use, defined synthetic formulations, and early human data. What is missing is the expensive part: larger controlled trials that show a clinical benefit in patients, followed by regulatory approval.
The most plausible targets are still the ones already chosen: persistent skin infection and clearing S. aureus from the nose in high-risk patients. In both, the medicine goes on the surface, MRSA is a real and growing problem, and the objection about blood levels does not apply.
If that happens, the result will be a licensed pharmaceutical product containing a defined cannabinoid at a specified concentration, prescribed for a named indication. It will not be cannabis, and it will not be something anyone makes at home. The Epilepsy topic (1309) shows what this path looks like when it is actually completed.
5. The Practical Warning
This matters more than the science, and it is why we are careful with this topic.
A skin infection that is not resolving needs a doctor. Cellulitis, abscesses and infected wounds get worse, and MRSA in particular can cause serious, occasionally life-threatening infection. Antibiotics work best early.
Applying an unregulated preparation to broken skin is a poor idea for a specific reason. Unregulated cannabis carries a documented risk of contamination with moulds and bacteria. Putting that into an open wound does the opposite of what you intend. Questions about homemade balms belong in the Topical topic (1310).
In vitro activity does not mean topical efficacy. In a dish a compound reaches the bacteria directly. In a patient it has to get past skin, pus, biofilm and blood proteins, and reach the right depth. The 2021 mouse data show this: topical CBD helped, but less than the standard ointment.
6. The Wider Point
Cannabis was in Western pharmacopoeias for about a century. It was used for an enormous range of conditions, almost none of them tested to any modern standard.
Some of those uses were probably real. The antibacterial line may be one of them: the 2008 work and the studies since suggest the laboratory activity is genuine. The tragedy of that period is not that the plant was banned. It is that cannabis was used for a hundred things and studied for none of them, so when the ban came there was nothing to defend but tradition.
Eighteen years after a solid confirmatory finding, this line is in a clearer position than before: tested in early trials, still no licensed product. The obstacles are pharmacology and money, not a conspiracy. That is a more accurate and more interesting complaint than suppression.
7. In Thailand
Cannabis flower is a controlled herb under the Notification of the Ministry of Public Health Re: Controlled Herbs (Cannabis), B.E. 2568, issued 26 June 2025. Flower may be dispensed only on prescription form PT 33 from an authorised practitioner. Each prescription covers no more than 30 days and cannot be refilled, and flower must come from a GACP-certified cultivation site. Online sale or advertising of flower is not allowed. There is no antibacterial indication for cannabis in Thailand or anywhere else.
If anyone reading this works in microbiology or dermatology in the region: the 2008 finding has reached early human trials, but no product has completed the path to approval. Is any group in Southeast Asia working on topical or nasal cannabinoid antibacterials? That would be worth knowing. A region with both cannabis cultivation and a serious MRSA burden could reasonably do this research.
This is general educational information, not medical advice. Suspected infections require medical assessment and appropriate antibiotics.